Cargando…

P04-19. Analysis of the binding of multiple clades of HIV-1 by a modified virus capture assay

Detalles Bibliográficos
Autores principales:	Peachman, K, Wieczorek, L, Polonis, VR, Alving, CR, Rao, M
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767948/ http://dx.doi.org/10.1186/1742-4690-6-S3-P47

Ejemplares similares

Cross-clade neutralization of HIV-1 by a monoclonal antibody obtained by immunization with liposomes containing lipid A and a synthetic MPER peptide
por: Matyas, GR, et al.
Publicado: (2012)

P04-22. Multispecific monoclonal antibodies bind to primary human macrophages and induce the production of protective chemokines, MIP-1α and MIP-1β
por: Weaver, KL, et al.
Publicado: (2009)

Soluble and bacteriophage T4 displayed gp41 mutant proteins as HIV-1 vaccine candidates
por: Gao, G, et al.
Publicado: (2012)

P05-04. Neutralizing antibodies induced by immunization with liposomal gp41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes
por: Matyas, GR, et al.
Publicado: (2009)

Neutralization and enhancement of trans infection by erythrocyte-bound HIV with antibodies and complement
por: Beck, Z, et al.
Publicado: (2012)

P04-12. Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assays
por: Brown, BK, et al.
Publicado: (2009)

Detection of antibodies to the α4β7 integrin binding site on HIV-1 gp120 V2 loop using a novel cell adhesion assay
por: Rao, M, et al.
Publicado: (2012)

Immunogenic selection of HIV-1 MPER epitopes for improved vaccine design
por: Wieczorek, L, et al.
Publicado: (2012)

P04-23. HIV-1 neutralization is impacted by the PBMC donor used for both virus growth and target cells, and the effects are neutralization reagent-specific
por: Wieczorek, L, et al.
Publicado: (2009)

Human Erythrocytes Selectively Bind and Enrich Infectious HIV-1 Virions
por: Beck, Zoltan, et al.
Publicado: (2009)

P04-03. Cross-clade neutralization analysis of plasmas from clade B, C and CRF01_AE HIV-infected donors
por: Binley, J, et al.
Publicado: (2009)

The impact of differences in viral entry and trafficking on the mechanism of HIV-1 neutralization
por: Cincotta, CD Macedo, et al.
Publicado: (2012)

P12-08. Membrane-specific antibodies that simultaneously bind to gp41 of HIV-1 and membrane lipid epitopes are induced by immunization with liposomes
por: Beck, Z, et al.
Publicado: (2009)

P04-28. Breadth and magnitude of neutralizing antibody responses in subjects infected with HIV-1 subtype D or recombinants in Rakai district, Uganda
por: Eller, L, et al.
Publicado: (2009)

P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group
por: Scarlatti, G, et al.
Publicado: (2009)

P04-04. The specific phospholipid binding and neutralizing activities of the anti-HIV antibody 4E10 are separable
por: Xu, H, et al.
Publicado: (2009)

P19-41. Full-length IMC expressing Renilla luciferase for neutralization assay using PBMC
por: Chenine, A, et al.
Publicado: (2009)

P04-52 LB. The importance of well-defined HIV-1 neutralization assays
por: Balla-Jhagjhoorsingh, SS, et al.
Publicado: (2009)

Antigenicity and immunogenicity of a novel, acute HIV-1 Tanzanian subtype C gp145 envelope protein for clinical development
por: Polonis, V, et al.
Publicado: (2012)

P04-11. Prevalence of neutralizing antibody responses in chronic clades A and D human immunodeficiency virus type 1 (HIV-1) infections
por: Njai, HF, et al.
Publicado: (2009)

P04-09. Induction of cross-clade neutralizing antibodies with a prime/boost vaccine strategy focused on a neutralizing epitope
por: Zolla-Pazner, S, et al.
Publicado: (2009)

P14-04. HIV-SELECTEST EIA and rapid test: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies
por: Khurana, S, et al.
Publicado: (2009)

P13-04. HIV positive women empowerment is equal to hiv prevalence reduction
por: Akolo, MM, et al.
Publicado: (2009)

P15-04. Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells
por: Todd, CA, et al.
Publicado: (2009)

In vivo effect of hydroxyethyl starch solution (HES 130/0.4) on different fibrinogen assays
por: Schött, U, et al.
Publicado: (2014)

P10-04. Mechanisms of HIV-1 detection by plasmacytoid dendritic cells
por: Lepelley, A, et al.
Publicado: (2009)

P04-20. Humoral immune response in acute HIV-1 infection
por: Mainetti, L, et al.
Publicado: (2009)

Antigen processing sites in gp120 are conserved across HIV virus clades
por: Yu, B, et al.
Publicado: (2012)

P04-46. Broadly cross-neutralizing activity in plasma of HIV-1 and HIV-2 infected individuals
por: Fenyö, E, et al.
Publicado: (2009)

P04-08. Monoclonal antibodies from patient with acute HIV-1 infection
por: Chen, W, et al.
Publicado: (2009)

P04-55 LB. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes
por: Zolla-Pazner, S, et al.
Publicado: (2009)

Further confirmation of broadly conserved, highly immunogenic cross-clade HIV CTL epitopes for inclusion in the GAIA HIV vaccine
por: De Groot, AS, et al.
Publicado: (2012)

P19-04. A synergistic effect of a combined bivalent DNA-protein anti-HIV-1 vaccine containing multiple T- and B-cell epitopes of HIV-1 proteins
por: Ilyichev, A, et al.
Publicado: (2009)

P04-29. HIV-1 neutralizing antibodies inhibit plasmacytoid dendritic cells infection
por: Lederle, A, et al.
Publicado: (2009)

P04-33. Mechanisms of HIV-1 antibody mediated inhibition in Monomac-1 and MDM
por: Fischetti, L, et al.
Publicado: (2009)

P04-45. Characterization of the plasma cell repertoire in acute HIV-1 infection (AHI)
por: Liao, L, et al.
Publicado: (2009)

P07-04. HIV-1 evolution in mother to child transmission and pediatric disease progression
por: Dispinseri, S, et al.
Publicado: (2009)

P04-04 Non-invasive biomarkers with high discriminant ability indicative of musculoskeletal health with ageing
por: Agyapong-Badu, Sandra, et al.
Publicado: (2022)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

P04-31. Abstract withdrawn
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_hkgmt3fd5nheo74d3d9hu0k6rs